 |
| Recombinant human lymphotoxin-α derivatives(rhLT28-171) |
| Lymphotoxin(LT) is an important member of the Tumor Necrosis Factor (TNF) family, a specific protein that causes destruction of tumors. Unlike TNF a,which exerts its tumor destruction functions through the biological effects of two specific receptors ,TNFR55 and TNFR75, but as the same time produce severe toxic side effects. FDZJ's rhLT28-171 regulates the biological effects of TNF 55 and TNF75, but with a lower toxicity. In both in vivo and in vitro tests, it is found that the tumor destruction effect of FDZJ's rhLT to be similar to that of TNF a . This product is approved by SDA to enter the clinical trial phase. FDZJ is the first enterprise in the world that had been approved to enter into the phase of clinical trial for rhLT. This project is supported as State Hi-Tech Development Project (863 Project) by State Ministry of Science and Technology in 2001 and 2002, respectively.
|
|
| Recombinant human parththyroid hormone derivatives (rhPTH1-34) |
| Natural human parathyroid hormone regulates both the estrogenic cells and osteoclast cells, and stimulates the remodeling of bone sclerotin. FDZJ re-engineers the genes of natural parathyroid hormone by recombinant technology to form a new type of protein that can be used for the treatment of osteoporosis or loss of bone issue. The re-engineering of the gene of natural human parathyroid hormone for the treatment of osteoporosis has been completed.
|
|
| Recombinant tissue type plasminogen activator (Reteplase) |
| Recombinant tissue type plasminogen activator (r-tPA) is internationally recognized as the best drug for the treatment of heart infarction. The pre-clinical pharmacology studies in respect of FDZJ's r-tPA have been completed and the Approval for clinical trial has been obtained from SDA. |
|
| Recombinant Fusion Protein of Human Tumour Necrosis Receptor 75 and Human IgG1 Fc (Etanercept) |
| Etanercept is intended for the treatment of Rheumatoid Arthritis by neutralizing TNFa and Lymphotoxin (TNFb). Currently, it is one of the most successful drugs for Rheumatoid Arthritis in the world. FDZJ has completed the sample manufacturing and progressed to the pre-clinical animal test. All date for clinical trial application by SDA are expected to complete in three months. |
|
| Recombinant Human Interleukin 1 Receptor Atagonist(IL-1ra) |
| IL-1ra is the natural antagonist for interleukin 1, which is the key factor of inflammation. Its indication is for the treatment of Rheumatoid Arthritis. FDZJ has finished the sample manufacturing and progressed to pre-clinical animal test. All date for clinical trial application by SDA are expected to complete in three months. |
|
| This page outlines FDZJ drug development portfolio. The content of the portfolio will change over time as new compounds progress from discovery to development. Due to the nature of the drug development process, it is not unusual for some compounds, especially those in early stages of investigation, to be terminated as they progress through development. For competitive reasons, some projects have not been disclosed and some project types may not have been identified. |
|
沪ICP备10027510号-1